Q3 2021
Released Oct 8, 2021, before the open
10-Q filed Nov 4, 2021, 35 days after period end · 0001493152-21-027249
Q3 2021 · 10-Q
Revenue$2.58M$2.58M +21.5% vs Q3 2020+13.8% vs Q2 2021
Net Income-$1.22M-$1.22M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.12-$0.12 N/M vs Q3 2020N/M vs Q2 2021
Gross Profit$1,360,000+11.0%
Operating Income-$802,000N/M
Operating Cash Flowderived-$910,000N/M
Free Cash Flowderived-$923,000N/M
Margins · derived
Gross margin52.8%−5.0 pt vs Q3 2020
Operating margin-31.1%+12.8 pt vs Q3 2020
Net margin-47.4%+0.3 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $2.58M | $2.12M | $3.10M | $1.72M |
| Net Income | -$1.22M | -$1.01M | -$744.00K | -$566.00K |
| EPS Diluted | -$0.12 | -$0.12 | -$0.10 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR